We have previously shown that an antisense phosphorothioate (PS) oligodeoxynucleotide has potent anti-human cytomegalovirus (HCMV) activity (GS Pari, AK Field &JA Smith, Antimicrobial Agents and Chemotherapy 1995, 39: 1157-1161). We have now used a modified PS oligonucleotide havingthree 2'-O-methyl nucleotides at the 3' end and four2'-O-methyl nucleotides at the 5' end, containing a cholesteryl moiety linked to the 3' end by a novel thiono-triester linkage. This compound, UL36ANTI-M, is superior to the PS (UL36ANTI) version with respect to antiviral potency, melting temperature and nuclease resistance. Also, we show that cellular association for this oligonucleotide is rapid, occurring within 15 min after treatment and is about 12-fold higher when compared to UL36ANTI. This increased rate of cellular association also correlates with antiviral properties in that a 15 min incubation with UL36ANTI-M was sufficient to achieve 75% inhibition of viral DNA replication and complete inhibition was achieved after only a 1 h pretreatment. In addition confocal microscopic examination showed a change in subcellular distribution from perinuclear to nuclear for oligonucleotides in HCMV-infected human fibroblasts.
Introduction
Human cytomegalovirus (HCMV) has a large (240 kb) linear dsDNA genome (Mocarski, 1993) . In cell culture, HCMV, like all herpesviruses, replicates in the nucleus of the cell. However, in contrast to other herpesviruses, HCMV replication is limited almost exclusively to normal diploid human fibroblasts (Mocarski, 1993) . Viral replication proceeds via a cascade of expression of gene products where immediate-early genes are expressed first, primarily within the first few hours of infection (Ho, 1991; Mocarski, 1993) . These immediate-early proteins are primarily involved in the transcriptional activation ofHCMV early genes, which are required for viral DNA replication (Iskenderian et al., 1996; Mocarski, 1993) . Therefore it would seem plausible that a rational drug target would be one that is far upstream in the reproductive cycle, before the initiation of DNA replication.
In previous reports we demonstrated the potent antiviral activity of a phosphorothioate (PS) antisense oligonucleotide complementary to the intron-exon donor region of HCMV pre-mRNA encoding immediate-early proteins UL36 and UL37 (Smith & Pari, 1995; Pari et al., 1995; Tenney & Colberg-Poley, 1991a,b; Colberg-Poley et al., 1992) . These gene products are required for HCMV origin-dependent DNA replication . The oligonucleotide, UL36ANTI, has IC so and IC 90 values of approximately 0.06 and 0.15 flM, respectively .
In this report we have altered the original 20 base UL36ANTI PS oligonucleotide by introducing two modifications on the same compound. This new compound, UL36ANTI-M, has four 2'-O-metyl nucleotides on the 5' end and three 2'-O-methyl nucleotides on the 3' end. In addition, one cholesteryl molecule is linked between the last two bases on the 3' end with a novel thiono-triester linkage (Zhang et al., 1995) . Analyses of anti-HCMV activity, cellular uptake, subcellular localization and in vitro stability were performed. To a stirred solution of the bis(diisopropylamino)chlorophosphine (1.56 g, 5.84 mmol) and triethylamine (1.22 mL, 0.89 g, 8.76 mmol) in THF (3.6 mL) was added dropwise cholesteryl-3-carboxy-6-hexanol (3.10 g, 5.84 mmol) in THF (4 mL) at O°C. Mter stirring for 1 h at room temperature, the reaction mixture was filtered and the filtrate was concentrated to an oil. The oil was dissolved in 15 mL of anhydrous pentane and filtered. The solvent was removed under reduced pressure. The mixture was again dissolved in 15 mL of anhydrous pentane and filtered to remove the remaining precipitates. The solvent was evaporated under the reduced pressure to give 0-(cholesteryl-3-carboxyamino-6-hexyl)-phosphordiamidite as a colourless sticky oil (4.38 g, 98.4% yield): 31p NMR (CDCI 3 ) 0 136.17.
Materials and Experimental Procedures
To a stirred suspension of 5'-DMT-dCtBA (1.5 g, 2.06 mmol) in CH 2Cl2 (7.5 mL) was added 0-(cholesteryl-3carboxyamino-6-hexyl)-phosphordiamidite (2.35 g, 3.09 mmol) in CH 2Cl2 (13.1 mL) under nitrogen. To the resulting mixture was added dropwise a solution of tetrazole (0.144 g, 2.06 mmol) in acetonitrile (8.4 mL). After the mixture was stirred for 5 h at room temperature, the solvent was removed at reduced pressure to give a foamy solid. The crude product was purified by flash column chromatography (eluant CH 2CI2:EtOAc:Et3N, 70:20:10) to give 5' -DMT-dCtBA-O-(cholesteryl-3-carboxyamino-6-hexyl)-phosphoramidite as a white foam (2.58 g, 90.4% yield): TLC Rf 0.63 (CH 2CI2:EtOAc:NEt3 , 45:45:10); 31p NMR (CDCI 3 ) 0 158.90, 159.25.
Synthesis and purification of oligonucleotides
All unmodified or triester-containing phosphorothioate oligonucleotides were synthesized on a 1 umol scale following the standard protocol using an automated synthesizer (Millipore 8909 Expedite). The modified phosphoramidite, 5'-DMT-dCtBA-0-(cholesteryl-3-carboxyamino-6-hexyl)-phosphoramidite, was dissolved in dichloromethane and diluted with acetonitrile to acetonitrile: dichloromethane (1:1) at a final concentration of 50 mg mL-1. For phosphorothioate oligonucleotides, the iodine oxidation step was replaced by sulphurization with 3H-1,2-benzodithiol-3-one-1,1-dioxide (Beaucage reagent). The thiono-triester phosphorothioate oligonucleotides were synthesized using the phosphoramidites protected by the base labile tert-butylphenoxyacetyl (tBA) group on the exocyclic amine (dA, dC and dG). Treatment for 2 h with ammonium hydroxide at room 256 temperature was carried out to cleave the oligomer from the support and deprotect the nucleoside bases. Oligonucleotides were purified by PAGE and desalted using a C-18 SEP-PAK cartridge.
Synthesis and purification of fluoresceinlabelled oligonucleotides
Fluorescein was conjugated to the 5' end of the oligonucleotides by the phosphoramidite method using an automated DNA synthesizer. Fluorescein-ON phosphoramidite was purchased from Clontech. Treatment for 2 h with ammonium hydroxide at room temperature was carried out to cleave the oligomer from the support and to deprotect nucleoside bases. Oligonucleotides were purified by PAGE, and desalted using a C-18 SEP-PAK cartridge. The efficiency of fluorescein labelling was determined using a spectrofluorometer (excitation 488 nm, emission 520 nrn). Efficiency of labelling data was used to adjust the amount of oligonucleotide so that direct comparison of oligonucleotide uptake could be performed. Efficiencies were all about equal, ranging from 92-96%.
Determination of melting temperature (T,J
Thermal melting data were collected from a Varian CARY1E UV-Vis spectrophotometer. Melting temperatures were determined for the duplexes of unmodified or modified oligonucleotides with the complementary DNA. The complementary DNA (30mer) was 5 bases longer in the 3' and 5' directions: 5' CCGTCTGTTCGCAAG-GTAAGCCCCACGTCG 3'. Each oligonucleotide (1 nmol) and its complementary DNA (l nmol) were dried by speed vacuum and dissolved in 100 /-lL Ixmelt buffer (100 mM NaCI, 10 mM HEPES pH 7.0, 10 mM MgCI 2 ) . The sample was subjected to rapid annealing on a Hybaid Thermal Cycler by heating to 90'C for 1 min and cooling down to 30°C over 1 min, and then placing on ice for 2 min. The sample volume was brought up 1.5 mL with 1xmelt buffer, placed into cuvettes and capped. The sample was then reheated to 90°C from 10°C at a rate of O.5°C min"! and theA 260 was continuously recorded. Data were interpreted using the Igor software program (Wavetronics).
Antiviral assays
Human foreskin fibroblasts cells (HFF) were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS as previously described (Smith & Pari, 1995; Pari et al., 1995) . For standard antiviral evaluations, cells were seeded in 6 em diameter dishes at a density of 2x10 5 cells per dish 24 h prior to the initiation of antiviral assays. Cells were then washed three times with PBS and pretreated as indicated with different concentrations of oligonucleotides for various times prior to infec-tion in Opti-MEM reduced serum media (Gibco BRL). HFF cells divide normally and become confluent in this media formulation (Z Zhang, JA Smith, AP Smyth, J-Y Tang, WEisenberg & GS Pari, unpublished results).
Following oligonucleotide incubation, cells were washed three times with PBS and infected with HCMV (strain AD169) for 1 h, washed once with PBS, and oligonucleotide was added back at the same concentration. Shorter duration oligonucleotide incubations and/or incubation with oligonucleotides post-infection (p.i.) were performed as indicated.
At 6 days p.i. total cellular DNA was extracted directly on the dish with lysis buffer (0.4 M NaOH, 10 mM EDTA). Celilysates were transferred to a 1.5 mL microcentrifuge tube and heated at 95"C for 10 min and transferred to Zeta-Probe nylon membrane using a dot blot apparatus (Gibco BRL). Blots were hybridized with an HCMV DNA-specific probe as described previously (Smith & Pari, 1995; Pari et al., 1995) . Dot blots were scanned and quantified using Scan Analysis software (Biosoft). IC 90 values were generated using data obtained from dot blot analysis of HCMV DNA from at least four separate experiments. This data was plotted and exact IC 90 values were determined by interpolation. Table 1 . T m of the modified HCMV oligonucleotides.
Anti-HCMV cholesteryl-modified oligonucleotide

Treatment of cells with oligonucleotides and confocal microscopy
HFF cells were plated in chamber slides at a density of lxl0 4 per chamber in complete medium. Cells were treated as for antiviral assays except 5' end fluorescent-labelled oligonucleotides were used at a concentration of 0.4~in Opti-MEM with 0% serum. Cells were incubated with oligonucleotide for 3-15 h, washed three times and either infected with HCMV (ADI69) (m.o.i.e L) for 1 h or mockinfected, washed once with PBS and allowed to incubate for 1-15 h. Cells were then visualized unfixed using a Bio-Rad MRC600 confocal microscope. Evaluation of cell growth and cytotoxicity by the MTS assay Antisense oligonucleotides were incubated with HFF cellsin 200 IJ.L of Opti-MEM media that were seeded in 96-well Increased rate and amount of cellular association of cholesteryl-modified oligonucleotides Initially we determined the relative differences in cellular uptake between the original PS compound (UL36ANTI), a 4x4 2'-O-methyl oligonucleotide (UL364X4) which contains four 2' -O-methyl nucleotides at the 5' and 3' ends, and the modified cholesteryl containing compound (UL36ANTI-M). FCM analysis of cellular association was performed in the presence and absence of virus. HFF cells were incubated with either UL36ANTI compound, UL36ANTI-M or UL364X4, all labelled at the 5' end with fluorescein. Fig. l(a) shows that oligonucleotide uptake in HFF cells is approximately 12-fold higher for the cholesteryl-modified oligonucleotide when compared to the PS compound (UL36ANTI) or UL364X4 after a 240 min incubation. Cellular association after a 30 min incubation with UL36ANTI-M oligonucleotide was almost sevenfold higher than an overnight (900 min) incubation with the PS oligonucleotide UL36ANTI or UL364X4 (Fig. 1a) . These experiments indicate that there is an increase in the rate and degree of cellular association for the cholesteryl-conjugated oligonucleotide UL36ANTI-M over the unmodified PS oligonucleotide or the 2' -O-methyl modified UL364X4.
Cellular association assays and flow cytometry (FCM) analysis
We also investigated the ability of viral infection to influence the degree of oligonucleotide cellular association.
Results
Northern blot analysis of UL36 mRNA HFF cells were treated with UL36ANTI-M at 0.08,0.04 and 0.02 11M for 1 h, oligonucleotide was removed and cells were washed three times with PBS. Cells were then infected with HCMV (rn.o.i. 0.8) for 6 h. Total cell RNA was extracted and samples were treated exactly as described previously (Smith & Pari, 1995) . Table 1 shows the oligonucleotides used in this study and their relative melting temperatures, as well as a schematic view of the cholesteryl-modified internucleotide linkage for the UL36ANTI-M antisense oligonucleotide.
plates at a density of 1000 cells well-l. Control cells Were treated the same as test samples except that no oligonucleotide was added. Cells were allowed to incubate with oligonucleotide for 15 min, 30 min, 1 hand 4 h, and media was then replaced with fresh media that did not contain oligonucleotide.For the 6 day exposure, oligonucleotidewas incubated with cells for a 6 day period without a media change. After incubation, cells were assayed for cell growth using the CellTitre 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega) according to manufacturer's instructions. (Coulter) instrument equipped with a 488 nm laser,gating on live cells was discriminated by propidium iodide uptake. Fluorescent pulses were monitored using the first PMT tube, FL1 (a 550 nm dichroid long pass filter with a 525 nm band pass filter); 10000 events were analysed.Data are reported as mean log fluorescence values. In these experiments we pretreated cells for 1 or 15 h with UL36ANTI-M, washed out oligonucleotide, and then infected cells for 1 h. Cells were harvested and assayed for cell association by FCM analysis 4 h post-infection. The results of these experiments are shown in Fig. l(b) . The relative amount of oligonucleotide associated with HFF cells was unaffected by HCMV infection. Therefore we concluded that the presence of virus did not substantially change the amount of oligonucleotide associated with HFF cells.
HCMV infection of HFF cells changes the subcellular distribution of oligonucleotides
The data from the cell association experiments indicated that HCMV infection had little effect on the degree of uptake of oligonucleotides. We next sought to determine if HCMV infection influenced the subcellular localization of oligonucleotides. Cells were pretreated with fluoresceinconjugated oligonucleotides for various times, infected or mock-infected and visualized using confocal microscopy. Fig. 2(a,b) shows uninfected cells incubated for 4 h with UL36ANTI or UL36ANTI-M. Cells incubated with either oligonucleotide displayed perinuclear fluorescence, indicating that very little oligonucleotide is present in the nucleus. The fluorescence pattern observed with the cholesteryl-conjugated oligonucleotide (Fig. 2b) is more intense, which is consistent with the cell association data showing that more of this oligonucleotide is associated with cells. However, when HFF cells were infected with HCMV at an m.o.i. of 1 and viewed 4-6 h p.i., the fluorescence pattern changed from perinuclear to a distinct intense nuclear pattern (Fig. 3 ). This pattern of nuclear fluorescence could be seen as early as 2 h p.i. (data not shown). Incubation with fluorescein alone gave no distinct fluorescence pattern. Oligonucleotides that were not complimentary to HCMV genomic sequences were also localized to the nucleus in the presence of HCMV infection (data not shown). 
UL36ANTI-M is twofold more active than the unmodified PS oligonucleotide
Since UL36ANTI-M was associated with cells at a higher rate and to a higher degree, we sought to determine if these properties could confer a more potent antiviral effect. We previously reported that the PS antisense oligonucleotide (UL36ANTI) required pretreatment in order to achieve any significant antiviral activity (Smith & Pari, 1995; Pari et aL, 1995) . Initially we used the same procedure, which was to pretreat with oligonucleotide for 15 h prior to HCMV infection using the modified antisense oligonucleotide UL36ANTI-M. The antiviral activity,with respect to inhibition of HCMV DNA replication, ofUL36ANTI-M was compared to that of the unmodified UL36ANTI oligonucleotide and UL364X4. In addition, two mismatch cholesteryl-containing control oligonucleotides were also tested. These oligonucleotides, UL36MMI and UL36MM2, contained base changes which result in a 3 and 2 bp mismatch, respectively, when hybridized with UL36/37 pre-mRNA. Qpantification of DNA dot blots is shown in Fig. 4 . UL36ANTI-M was approximately twofold more active than the unmodified PS version. UL36ANTI-M inhibited over 90% of HCMV DNA accumulation at a concentration of 0.04~(n=4) (IC 9o 0.04), whereas the UL36ANTI achieved 90% inhibition at a concentration of 0.08( IC 9o 0.08) (Fig. 4) ; the control oligonucleotide, UL36SENSE-M, had no effect on HCMV DNA replication at the highest concentration. Since oligonucleotides containing four consecutive guanosines have shown antiviral activity in other systems we included other 4G cholesteryl control oligonucleotides (Table 1 ; UL36MMI and UL36MM2). These oligonucleotides also had little effect on HCMV DNA replication (Fig. 4) . The compound UL364X4 (IC 9o 0.08), which contains four 2'-O-methyl substitutions at the 3' and 5' ends, had a similar activity profile to UL36ANTI (IC 9o 0.08) (Fig. 4) .
UL36ANTI-M inhibits accumulation of UL36 mRNA
In previous studies involving UL36ANTI we demonstrated an antisense mechanism of action by showing a decrease in the accumulation of the steady state level of UL36 mRNA (Smith & Pari, 1995) . In order to demonstrate the same antisense mechanism with the modified oligonucleotide UL36ANTI-M we analysed the degree of inhibition of UL36 mRNA in the presence of UL36ANTI-M and mismatch and sense control oligonucleotides. Oligonucleotides were preincubated with cells for 1 h, cells were washed and infected, and total cell RNA was extracted 6 h p.i, A sequence-specific dose-dependent decrease in UL36 mRNA was achieved when UL36 oligonucleotides were used to treat cells. However, no effect on UL36 mRNA was seen when control oligonucleotides were used (Fig. 5 ). Cellular toxicity is reduced with decreasing exposure to UL36ANTI-M Cellular toxicity assays were performed using UL36ANTI-M and UL36ANTI as described in Materials and Experimental Procedures. When UL36ANTI-M was incubated with cells for 6 days, cell growth was inhibited 50% at an oligonucleotide concentration of 2 u.M, However, no cell growth inhibition was observed at oligonucleotide concentrations as high as 8 flM when UL36ANTI-M was incubated with cells for a 15 min to 4 h period followed by a medium change that did not contain oligonucleotide. Fifty percent growth inhibition with UL36ANTI was achieved at an oligonucleotide concentration of 60 u.M in the 6 day assay.
HFF cells treated with antisense and control oligonucleotides were infected for 6 h and total cellular RNA was extracted. Equal amounts of RNA was separated on a 1% formaldehyde-agarose gel and transferred to nylon membrane. Blots were hybridized with an RNA probe to UL36 mRNA and 18S RNA. Oligonucleotides used to treat cells are shown above and oligonucleotide concentrations are shown below the autoradiogram.
Potent antiviral activity can be achieved with as little as a 15 min pretreatment with
UL36ANTI-M
Because of the observed increased rate of uptake for the cholesteryl-modified oligonucleotide, UL36ANTI-M, we investigated the possible correlation between shorter cellular exposure times to oligonucleotide and antiviral activity. HFF cells were treated with oligonucleotides at a concentration of 0.4 flM for various times and cells were then washed three times with PBS and infected with HCMV (m.o.i.=O.4) for 1 h. Cells were washed and fresh medium was added that did not contain oligonucleotide. After only a 15 min pretreatment with UL36ANTI-M, HCMV DNA replication was inhibited 75% compared to untreated control cells (Fig. 6) . Oligonucleotides UL36ANTI and UL364X4 had no effect on HCMV DNA replication after a 15 min pretreatment. Fifty percent inhibition was achieved after a 1 h pretreatment with UL36ANTI and UL364X4 oligonucleotides, compared to a complete inhibition of DNA replication with UL36ANTI-M at this time point (Fig. 6 ). This experiment indicated that the increased rate of uptake observed with UL36ANTI-M could influence the time of cellular exposure to oligonucleotide needed to achieve a significant antiviral effect. Some inhibition of DNA replication was observed with Antiviral Chemistry & Chemotherapy 8(3)
Discussion
In this report we have used a modified antisense phophorothioate oligonucleotide to inhibit HCMV DNA replication. This modified oligonucleotide (UL36ANTI-M) has four 2'-Ovmcthyl-substituted nucleotides at the 5' end and three at the 3' end of the molecule and a cholesteryl moiety at the 3' end conjugated by a novel thiono-triester linkage (Zhang et al., 1995) . We used the combination of 2'-O-methyl chemistry and cholesteryl primarily for two reasons. First, the introduction of 2'-0methyl nucleotides has been shown to increase stability and melting temperature of oligonucleotides. Second, the conjugation of cholesteryl to the oligonucleotide increased the rate and degree of cellular uptake. This report investigated if these properties could affect the antiviral activity with respect to potency and/or duration of treatment. In addition, we also show thai: subcellular localization of oligonucleotide is influenced by the presence of HCMV. The addition of cholesteryl facilitated the uptake of the oligonucleotide such that the amount associated with the cell was approximately 10-fold higher than the PS version with the same sequence. However, this higher degree of uptake observed for UL36ANTI-M did not yield a proportionally more potent compound compared to the unmodified UL36ANTI when a 4-15 h pretreatment regime was employed. Only a twofold increase in antiviral activity was observed. This demonstrates that, at least in this particular case, a several fold increase in uptake does not necessarily correlate with antiviral activity. Nevertheless, we were able to demonstrate that it is advantageous to have an antisense oligonucleotide with an increased rate of cellular uptake. After only a 15 min exposure to oligonucleotide, cells were able to internalize enough compound so that a significant antiviral activity could be achieved. This antiviral effect was sequence-specific since a Sense strand 2'-Ovmethyl oligonucleotide with cholesteryl in the same position had only a small antiviral effect. This 'non-specific' effect decreased as time of exposure increased and may be due to effects on viral adsorption, since the largest inhibitory effect was seen only after a 15 min incubation time. At this time after addition there may be a large enough amount of oligonucleotide at the surface of the cell to have a slight interference with viral attachment. We also used two other control oligonucleotides in longer preincubation studies, UL36MMI and UL36MM2. These oligonucleotides retained the 4G motif at the 5' end but were mutated in other areas of the compound resulting in base-pair mismatches. This is an important control since antiviral effects can occur with certain oligonucleotides containing four consecutive guanosines (Buckheit et aI., 1994) .
The use of cholesteryl-conjugated antisense oligonucleotides for viral targets is not new (Stein et al., 1991; Letsinger et aI., 1989) . The addition of cholesteryl to PS 262 oligonucleotides targeted to the splice acceptor site in human immunodeficiency virus (HIV) increased the antiviral activity about 16-fold (Letsinger et aI., 1989) . In these studies however, no information on cellular uptake, subcellular distribution or toxicity was furnished. There have also been reports that 5'-cholesteryl-containing oligonucleotides inhibit syncytium formation and infection of HIV-I and HIV-2 (Stein et aI., 1991) . In the case of HCMV antisense inhibition,S'-conjugated cholesteryl compounds had no antiviral activity (Z Zhang, JA Smith, AP Smyth, J-Y Tang, WEisenberg & GS Pari, unpublished results). Many studies have examined the ability of cholesteryl-conjugated oligonucleotides to associate with cells and effects on efficacy. These studies examined the uptake and effects of cholesteryl-rnodified antisense oligonucleotides in transformed fibroblasts or lymphocytes (Reed etal., 1995; Zhang et al., 1995; Boutorin et al., 1989; Kreig et aI., 1993) . In this report we have investigated antiviral activity and cellular uptake in normal human cells, which seem to display different characteristics with respect to uptake and subcellular distribution in that most of the oligonucleotide remains in the cytoplasm in uninfected cells. In addition we have provided information about how modified and unmodified oligonucleotides act in HFF cells infected with HCMV, a virus that produces dramatic changes in normal cellular functions (Mocarski, 1993) .
The cholesteryl antisense compound studied here, UL36ANTI-M, was more cytotoxic than UL36ANTI, the full PS compound. However, this toxicity was alleviated by treating cells for a shorter time and by not adding oligonucleotide back to the media after infection. Also, since uptake ofUL36ANTI-M is rapid there was no need to add oligonucleotide back to the media even after a short (30 min) treatment, although a 4 h treatment with any of the other unmodified antisense oligonucleotides at a concentration of 004 u.M gave the same effect. In addition, a 1 h pretreatment time was also sufficient to demonstrate a dose-dependent inhibition ofUL36 mRNA.
This report also demonstrated that nuclear localization of oligonucleotides was most efficient after HCMV infection. Although the data presented here showed nuclear localization in HFF cells only for the cholesteryl compound, all oligonucleotides displayed this pattern after infection (Z Zhang, JA Smith, AP Smyth, J-Y Tang, W Eisenberg and GS Pari, unpublished results). Nuclear localization was observed as early as 2 h p.i. This is important since the target sequence for this antisense oligonucleotide is the pre-mRNA of an immediate-early gene that is present only in the nucleus. Infection-facilitated nuclear localization may be the reason we have not found it necessary to use lipid carriers when using HFF cells, which is contrary to many antisense scenarios (Jaroszewski & Cohen, 1990; Crooke, 1993; Bennett et al., 1992) , perhaps because infection itself efficiently delivers oligonucleotide to the nucleus. In uninfected cells we observed a perinuclear distribution of oligonucleotides; this has also been reported in various other cell types (Jaroszewski & Cohen, 1990; Crooke, 1993) . At this time we do not know the nature of infection-induced nuclear localization. It may be that upon entry into the nucleus, virus may allow oligonucleotide to penetrate efficiently the nucleus through nuclear pores. However, since the events ofvirus entry into the nucleus are poorly understood, the exact nature of oligonucleotide nuclear entry is not easy to postulate.
Infection did not potentiate the total cellular association of oligonucleotide since 'the amount of oligonucleotide associated with cells did not appreciably change. These experiments were done after a pretreatment with oligonucleotide. It has been reported that infection in the presence of oligonucleotide can increase uptake (Gao et al., 1990) . The studies using fluorescein-conjugated oligonucleotide investigated the relative differences in uptake and subcellular distribution. Fluorescein fluorescence quenching can occur when using tagged oligonucleotides. However, since our studies were comparative we do not see quenching as a hindrance to the interpretation of the data presented here.
We have shown that the 3'-cholesteryl modified antisense oligonucleotides have properties that are advantageous in cell culture. The most impressive of these is the rapid uptake into cells, which can confer a potent antiviral effect. It will now be interesting to investigate if these properties have the same advantages in vivo
